Abstract 942: HPK1, hematopoietic progenitor kinase 1, is a promising therapeutic target for cancer immunotherapy
David Ciccone(Harvard University), Neelu Kaila, Vad Lazari(Charles River Laboratories (United Kingdom)), Alan Collis, Mark A. Ashwell(Arqule (United States)), Michael A. Briggs(Charles River Laboratories (United Kingdom)), Peter J. Tummino(Intarcia Therapeutics (United States)), J. Robledo Montaña(Charles River Laboratories (United Kingdom)), Jennifer L. Rocnik(Novartis (United States)), Christine Loh(Ensemble Therapeutics (United States)), Ian D. Linney(Charles River Laboratories (United Kingdom))
Cited by 1
Related Papers
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
|Nature|1999|1.9k
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
|Nature|2012|1.8k
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
|Journal of Biological Chemistry|2002|1.4k
Residence Time of Receptor−Ligand Complexes and Its Effect on Biological Function
|Biochemistry|2008|550